Alzamend Neuro (ALZN) Stock: Buy, Sell, or Hold?
ALZN - Alzamend Neuro, Inc. Common Stock
$1.79
0.06 (3.46%)
▲
5d:
-7.74%
30d:
+7.83%
90d:
+49.16%
WAIT
LOW Confidence
Analysis Updated: Sep 28, 2026 12:00 AM ET
Earnings: Sep 09, 2026
0d
Get Alerted When ALZN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ALZN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ALZN shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ALZN is currently trading at $1.79, which is considered extended relative to its 30-day fair value range of $1.58 to $1.84.
Technical Outlook: Technically, ALZN is in a strong uptrend. Immediate support is located at $1.73, while resistance sits at $1.95. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: ALZN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $26.00 (+1402.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ALZN is in a strong uptrend. Immediate support is located at $1.73, while resistance sits at $1.95. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: ALZN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $26.00 (+1402.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.58 -
$1.84
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
31.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 1402.9% below Wall St target ($26.00)
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.58 -
$1.84
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.73
Resistance Level
$1.95
Current Trend
Strong Uptrend
Technical data as of
Sep 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.67
Wall Street Target
$26.00
(+1402.9%)
Share & Embed Analysis
Last updated: September 29, 2026 10:03 AM ET
Data refreshes hourly during market hours. Next update: 11:03 AM
Data refreshes hourly during market hours. Next update: 11:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALZN showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Milton C Ault III
BUY
108388 shares
2026-04-14
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 62 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 56 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 69 BUY |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$254 | 68 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$95 | 43 HOLD |
